Status and phase
Conditions
Treatments
About
This is a single center imaging study investigating the use of PET with 68Ga-citrate in patients with DLBCL or BCLU.
Full description
This is a single center feasibility imaging study in patients with diffuse large B-cell lymphoma (DLBCL) or B-cell Lymphoma, Unclassifiable with features between DLBCL and Burkitt's (BCLU). Study participants will undergo PET/MRI of the whole body with 68Ga citrate.
The study will include at least 5 patients with double hit lymphoma and 5 patients with DLBCL with an additional 5 more patients as expansion once the dose level has been established. Patients with DLBCL will be included once an optimal dose level for the resolution of cancer lesions has been established.
Sex
Ages
Volunteers
Inclusion criteria
Histologically confirmed DLBCL or BCLU.
Presence of palpable or radiographically measurable disease of at least 1.5 cm in longest dimension.
Available prior CT or PET/CT scan done in the last 8 weeks for comparison
Prior chemotherapy or radiation to the measurable lesion must be completed at least 14 days prior.
Adequate renal function with estimated creatinine clearance ≥50 mL/min (by the Cockcroft Gault equation)
No contraindications to MRI (e.g. pacemaker, aneurysm clips, severe claustrophobia)
Ability to sign a study-specific internal review board (IRB) approved consent prior to study entry. Patients must be able and willing to consent and undergo study procedures.
Age ≥18 years old
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
0 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal